Asset Details
Do you wish to reserve the book?
Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody–associated vasculitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody–associated vasculitis
Do you wish to request the book?
Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody–associated vasculitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody–associated vasculitis
2013
Overview
Studies in animal models suggest that complement activation is crucial in the pathogenesis of anti-neutrophil cytoplasmic antibody–associated vasculitis (AAV). Here we investigate the circulating complement activation profile of 66 patients with active stage AAV compared to that of 54 patients with AAV in remission. Plasma levels of C3a, C5a, soluble C5b-9, and Bb, all determined by enzyme-linked immunosorbent assay, were significantly higher in active stage than in remission of AAV, while plasma levels of properdin were significantly lower in the former than the latter disease stage. There was no significant difference in the plasma levels of C4d between active stage and remission. The plasma level of Bb in patients with active AAV significantly correlated with the proportion of total and cellular crescents in the renal biopsy, the erythrocyte sedimentation rate, and the Birmingham Vasculitis Activity Scores. Thus, systemic activation of complement by the alternative pathway takes place in human AAV. Circulating Bb might be a useful biomarker in assessing disease activity of AAV.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Adult
/ Aged
/ anti-neutrophil cytoplasmic antibody
/ Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - blood
/ Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - diagnosis
/ Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy
/ Complement Factor B - metabolism
/ Female
/ Humans
/ Immunosuppressive Agents - therapeutic use
/ Male
